Free tool
Cell therapy stocks
We cover 4 companies grouped under the Cell therapy theme. The median market value in the group is $11.37M. Across the group, the median move over the past trading day is −6.29%. Price change over the past year runs from −95.4% to −48.7% across the middle 80 percent of the group, with a median of −78.0%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
4 of 86 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| 0NLV.L | FamiCord AG | $21.73M | Micro cap | −61.12% |
| 311A.T | NPT Co Ltd | $20.81M | Micro cap | −43.33% |
| CYP.AX | Cynata Therapeutics Limited | $1.92M | Micro cap | −94.88% |
| CHM.AX | Chimeric Therapeutics Limited | $659.83K | Micro cap | −95.67% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.